

NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA (OR TO U.S. PERSONS), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW



## Press Release

**Dr. Bernd Ebeling**  
Corporate Communications

Fresenius SE  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2378  
F +49 6172 608-2294  
bernd.ebeling@fresenius.com  
www.fresenius.com

August 12, 2008

### **Fresenius SE successfully completes capital increase**

The new Fresenius SE shares were successfully placed today. In connection with the company's capital increase, 2,748,057 new ordinary shares were issued at a price of € 52.00 and 2,748,057 preference shares were issued at a price of € 53.00. The transaction has generated gross proceeds of approx. € 289 million, fully in line with Fresenius' financing plan.

The new shares are expected to be included in the quotation of the existing shares of Fresenius SE in the regulated market at the Frankfurt, Munich and Düsseldorf stock exchanges. They have full dividend entitlement for the fiscal year 2008.

Dr. Ulf Mark Schneider, Chairman of the Management Board of Fresenius SE commented: "The capital increase is a further component of the acquisition financing for APP Pharmaceuticals. This acquisition provides attractive growth opportunities for Fresenius Kabi's existing product portfolio in North America. At the same time, Fresenius Kabi achieves a leading position in the global I.V. generics market. The successful placement of the new shares reflects the confidence of the capital markets in our strategy. With this placement, the entire equity financing of the APP Pharmaceuticals acquisition has been completed within a few weeks."

Deutsche Bank and Commerzbank acted as Joint Lead Managers and Joint Bookrunners and WestLB as Joint Lead Manager for the offering.

NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA (OR TO U.S. PERSONS), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW

<b>Capital Increase Data</b>		
Issuer	Fresenius SE	
Transaction Structure	Capital increase without subscription rights	
Offering	2,748,057 new ordinary shares 2,748,057 new preference shares	
Placement of Shares	Private placement with German and international institutional investors	
Stock Exchanges	Regulated Market Frankfurt (Prime Standard), Munich, Düsseldorf	
Bank Consortium	Joint Bookrunner	Deutsche Bank AG, Commerzbank AG
	Joint Lead Manager	Deutsche Bank AG, Commerzbank AG, WestLB AG

#### **About Fresenius SE**

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approx. € 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide.

For more information visit the Company's website at [www.fresenius.com](http://www.fresenius.com).

THIS RELEASE IS FOR INFORMATION PURPOSES ONLY AND MAY NOT BE FURTHER DISTRIBUTED OR PASSED ON TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This release does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of Fresenius SE ("Fresenius") or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Fresenius or any member of its group or any commitment whatsoever. In particular, this release is not an offer of securities in the United States of America (including its territories and possessions), and securities of Fresenius SE may not be offered or sold in the United States of America absent registration under the Securities Act of 1933 (which Fresenius SE does not intend to effect) or pursuant to an exemption from registration.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. This includes the risk that the transaction will not be consummated or on other terms. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA (OR TO U.S. PERSONS), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW

This document is directed at and/or for distribution in the U.K. only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons being together referred to as "relevant persons"). This document is directed only at relevant persons. Other persons should not act or rely on this document or any of its contents.

The information contained herein is not for publication or distribution in Canada, Australia or Japan and does not constitute an offer of securities for sale in Canada, Australia or Japan.

Board of Management: Dr. Ulf M. Schneider (President and CEO), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler  
Supervisory Board: Dr. Gerd Krick (Chairman)  
Registered Office: Bad Homburg, Germany/Commercial Register No. HRB 10660